Cargando…
The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer
SIMPLE SUMMARY: The treatment of advanced non-small cell lung cancer (NSCLC) after the age of 65 raises age-related problems as the elderly are often affected by other diseases, not infrequently chronic, take drugs that may interfere with anti-cancer treatment and are sometimes unable to fully under...
Autores principales: | Spagnuolo, Alessia, Gridelli, Cesare |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136482/ https://www.ncbi.nlm.nih.gov/pubmed/37190247 http://dx.doi.org/10.3390/cancers15082319 |
Ejemplares similares
-
The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target—a narrative review
por: Spagnuolo, Alessia, et al.
Publicado: (2022) -
The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives
por: Rocco, Danilo, et al.
Publicado: (2020) -
Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with Immunotherapy
por: Rocco, Danilo, et al.
Publicado: (2023) -
Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer
por: Gridelli, C, et al.
Publicado: (2003) -
Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes
por: Rocco, Danilo, et al.
Publicado: (2023)